MedTrace Logo

Efficacy and Safety of Topical Methotrexate Gel 1% Coupled With Microneedling in Treatment of Warts

NCT05300009 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2022-03-29

No results posted yet for this study

Summary

To study the clinical efficacy of the topically applied MTX hydrogel preparation combined with microneedling to increase drug delivery and efficacy in comparison with cryotherapy in treatment of warts.

Conditions

  • Warts

Interventions

COMBINATION_PRODUCT

topical methotrexate hydrogel 1% coupled with microneedling.

Microneedling will be performed on each wart for a maximum 5 lesions per patient using dermapen (Ostar rechargeable dermapen, OB-DG 03N, Ostar Beauty Sci-Tech Co, Beijing, China) supplied with 12 needles arranged in rows. The penetration depth was adjusted at 2-mm, endpoint was pinpoint bleeding and the dermapen will be held by the hand in a vertical direction on the wart. Then topical methotrexate 1% gel will be applied on the lesions every session.

OTHER

Liquid nitrogen

The wart is frozen for 10 to 30 seconds until a 1- to 2-mm ice ball halo surrounds the targeted area. The sessions were performed every 2 week until complete clearance for a maximum of six sessions.

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Khulood F Alhakami, M.B.B.CH · Assiut University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-15
Primary Completion
2023-06-15
Completion
2023-08-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05300009 on ClinicalTrials.gov